Lyra Therapeutics (NASDAQ:LYRA) Lowered to Neutral at HC Wainwright

HC Wainwright lowered shares of Lyra Therapeutics (NASDAQ:LYRA – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has $2.00 target price on the stock, down from their previous target price of $12.00. A number of other research analysts […]

Leave a Reply

Your email address will not be published.

Previous post LightPath Technologies (NASDAQ:LPTH) Now Covered by Analysts at StockNews.com
Next post Microchip Technology (NASDAQ:MCHP) Given New $110.00 Price Target at KeyCorp